Nutcracker Therapeutics, Inc.

Nutcracker Therapeutics, Inc. is a biotechnology firm that develops advanced RNA therapeutics through a unique platform integrating RNA design, nanoparticle delivery, and manufacturing processes to address complex diseases. Founded in 2018 in Emeryville, US, Nutcracker Therapeutics specializes in RNA therapeutics. The company has successfully raised funding through four deals, with its latest being a Series C round in August 2021, secured with USD 144.

50 mn led by ARCH Venture Partners. Igor Khandros, one of the co-founders, currently serves as CEO. The firm operates without known parent companies or subsidiaries. Nutcracker Therapeutics specializes in advanced RNA therapeutics through a proprietary end-to-end platform that combines RNA design, nanoparticle delivery, and GMP biochip-based manufacturing.

Their core offerings focus on accelerating the development and production of RNA-based treatments for complex diseases. Utilizing a unique GMP-in-a-box approach, Nutcracker aims to reduce costs and enhance scalability in RNA therapeutic development, serving clinical investigators and medical institutions across North America, Europe, and Asia. Nutcracker Therapeutics generates revenue primarily through partnerships and collaborations with clinical institutions and other stakeholders in the healthcare sector. Their business-to-business (B2B) model involves contracts for the development and manufacturing of RNA therapeutics, with specific revenue structures including milestone payments and fees for access to manufacturing technologies.

Following the Series C funding of USD 144. 50 mn in August 2021, Nutcracker Therapeutics plans to enhance its pipeline of mRNA medicines for cancer. The funding will support the design and launch of new products aimed at addressing cancer treatments. The company is also targeting expansion into new markets and geographic regions, although specific regions and timelines have not been disclosed.